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ARTICLE
Engrailed 1 coordinates cytoskeletal reorganization
to induce myofibroblast differentiation
Andrea-Hermina Györfi1,2*, Alexandru-Emil Matei1,2*, Maximilian Fuchs3, Chunguang Liang3, Aleix Rius Rigau1,2, Xuezhi Hong1,2,
Honglin Zhu1,2,4, Markus Luber1,2, Christina Bergmann1,2, Clara Dees1,2, Ingo Ludolph5, Raymund E. Horch5, Oliver Distler6,
Jiucun Wang7,8,9, Bertram Bengsch10,11, Georg Schett1,2, Meik Kunz3, and Jörg H.W. Distler1,2
Transforming growth factor-β (TGFβ) is a key mediator of fibroblast activation in fibrotic diseases, including systemic
sclerosis. Here we show that Engrailed 1 (EN1) is reexpressed in multiple fibroblast subpopulations in the skin of SSc patients.
We characterize EN1 as a molecular amplifier of TGFβ signaling in myofibroblast differentiation: TGFβ induces EN1
expression in a SMAD3-dependent manner, and in turn, EN1 mediates the profibrotic effects of TGFβ. RNA sequencing
demonstrates that EN1 induces a profibrotic gene expression profile functionally related to cytoskeleton organization and
ROCK activation. EN1 regulates gene expression by modulating the activity of SP1 and other SP transcription factors, as
confirmed by ChIP-seq experiments for EN1 and SP1. Functional experiments confirm the coordinating role of EN1 on ROCK
activity and the reorganization of cytoskeleton during myofibroblast differentiation, in both standard fibroblast culture
systems and in vitro skin models. Consistently, mice with fibroblast-specific knockout of En1 demonstrate impaired
fibroblast-to-myofibroblast transition and are partially protected from experimental skin fibrosis.
Introduction
Fibrotic diseases are a major cause of morbidity and mortality,
accounting for ≤40% of the deaths in Western societies (Wynn,
2008). Systemic sclerosis (SSc) is the prototypical systemic fi-
brotic disease, characterized by excessive deposition of collagen
in skin and multiple other organs, leading to their dysfunction
(Gabrielli et al., 2009). The major effector cells in fibrosis are
activated fibroblasts, so-called myofibroblasts, which express
contractile proteins such as α-smooth muscle actin (αSMA)
and produce excess collagen (Hinz et al., 2012; Wynn and
Ramalingam, 2012). Resting fibroblasts are initially activated
by cytokines released from infiltrating leukocytes, both in
physiological responses such as wound healing and in fibrosis
(Distler et al., 2019). Of these cytokines, TGFβ plays a key role,
driving persistent fibroblast activation not only during disease
initiation, but also at later stages of fibrosis, when the inflam-
mation has subsided and fibroblasts remain endogenously ac-
tivated (Distler et al., 2019). TGFβ activates fibroblasts via a
complex network of multiple intracellular cascades (Lafyatis,
2014). These TGFβ-regulated intracellular pathways are main
targets of emerging antifibrotic therapies (Györfi et al., 2018).
Thus, discovery and characterization of novel mediators of the
profibrotic effects of TGFβ can provide new therapeutic op-
portunities in SSc (Distler et al., 2017).
Engrailed 1 (EN1) is a homeodomain-containing transcription
factor with essential, widespread roles in embryonic develop-
ment of different tissues including cerebellum, midbrain, skel-
eton, and limbs (Loomis et al., 1996; Wurst et al., 1994). While
EN1 expression persists in some cells such as mesencephalic
dopaminergic neurons during adulthood, most other cell types
silence the expression of EN1 after lineage commitment and do
not express EN1 under homeostatic conditions in adulthood
(Rekaik et al., 2015). However, a pathological environment can
induce the expression of EN1 in these cells to promote pheno-
typical adaptation. In tissues from patients with triple-negative
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breast cancer, for example, EN1 expression is up-regulated and
correlates with poor patient survival; moreover, EN1 expression
induces proliferation and migration of quintuple-negative breast
cancer cells (Kim et al., 2018). Depending on the context, EN1 can
regulate gene transcription either directly by binding to con-
served EN1-binding sites in the promoters of target genes or
indirectly by trans-activation or trans-repression by interacting
with other transcription factors, with subsequent modulation of
their transcriptional outcome (Alexandre and Vincent, 2003).
Of particular interest, En1 is transiently expressed during dermal
development in murine embryos in a distinct fibroblast lineage
(Rinkevich et al., 2015). In mice, En1-positive fibroblasts gradually
replace En1-negative fibroblasts in the developing dermis (Jiang
et al., 2018). The expression of En1, however, decreases rapidly
before birth. Former EN1-positive cells give rise to a subpopulation
of fibroblasts that has a high capacity for extracellularmatrix (ECM)
production and important roles in wound healing in adult murine
skin (Jiang et al., 2018; Rinkevich et al., 2015). However, the regu-
lation of EN1 in adult skin and its role in the pathological activation
of fibroblasts in tissue fibrosis have not been studied thus far.
In this study, we show that TGFβ reactivates the expression
of EN1 in a SMAD-dependentmanner with increased numbers of
EN1-positive fibroblasts in SSc skin. Imaging mass cytometry
(IMC) of paired skin biopsies from SSc patients (from ventral
and dorsal skin) show that EN1 is expressed by multiple fibro-
blast subpopulations in SSc. EN1 is a critical mediator of the profi-
brotic effects of TGFβ in adult fibroblasts: EN1 overexpression
in adult human dermal fibroblasts promotes fibroblast-to-
myofibroblast transition and collagen release, whereas knock-
down of EN1 prevents TGFβ-induced fibroblast-to-myofibroblast
transition. EN1 knockdown induces global transcriptomic changes
in TGFβ-stimulated fibroblasts, preventing induction of a pro-
fibrotic gene expression profile. EN1 trans-regulates gene ex-
pression by modulating the activity of transcription factors from
the C2H2 zinc finger family, in particular those from the specificity
protein (SP) subfamily. Chromatin immunoprecipitation followed by
sequencing (ChIP-seq) experiments for both EN1 and SP1 demon-
strate no direct binding of EN1 to the promoters of EN1-DEGs, but
EN1-driven modulation of SP1 binding to the promoter of fibrosis-
relevant genes. Mechanistically, changes of gene expression induced
indirectly by EN1 knockdown, in particular genes with predicted
regulation by SP transcription factors and especially with SP1 bind-
ing, lead to stabilization of microtubules and reduced Rho-associated
protein kinase (ROCK) activity, with subsequent prevention of TGFβ-
induced stress fiber formation, myofibroblast transition, and fibrotic
transformation of three-dimensional (3D) full-thickness skin equiv-
alents. Consistently, fibroblast-specific En1 knockout ameliorates
dermal fibrosis in three complementary inflammation-driven and
inflammation-independent mouse models of SSc. We thus char-
acterize EN1 as a mediator of TGFβ-induced fibroblast activation
and fibrosis.
Results
EN1 expression is up-regulated in fibrotic skin
We first analyzed the expression of different members of the EN
family of homeodomain-containing transcription factors in the
skin of patients with SSc. Immunofluorescence staining dem-
onstrated increased expression of EN1 and prominent staining,
with nucleocytoplasmic pattern, in dermal fibroblasts (identi-
fied as prolyl-4-hydroxylase-β [P4Hβ]–positive, CD45-negative
cells) in the skin of SSc patients (Fig. 1 A). The percentage of
EN1-positive fibroblasts was increased in SSc patients as com-
pared with healthy individuals (Fig. 1 A). Other cell populations
such as endothelial cells, leukocytes, and keratinocytes were
stained with lower intensity for EN1 than fibroblasts, and EN1
expression was not changed in SSc skin in these cells (Fig. S1).
Higher expression levels of EN1 were maintained in SSc fibro-
blasts for several passages in vitro. Cultured fibroblasts from SSc
patients expressed higher levels of EN1 mRNA and EN1 intra-
cellular protein and secreted higher amounts of EN1 as com-
pared with healthy dermal fibroblasts (Fig. 1, B and C). The
expression of En1 was also up-regulated in murine models of
skin fibrosis, with higher En1 protein levels in fibrotic mice as
compared with nonfibrotic controls (Fig. 1, D and E). Moreover,
the percentage of En1-positive fibroblasts (defined as En1+, Vi-
mentin+, CD45− cells) was highly increased in the dermis of
bleomycin-challenged mice and in the hypodermis of Tsk-1 mice
in comparison with their respective controls (Fig. 1, F and G). In
contrast to EN1, the other member of the EN family, EN2, was
expressed at very low levels and did not differ between fibrotic
and healthy human skin.
EN1 is expressed by multiple fibroblast subpopulations in both
ventral and dorsal SSc skin
To evaluate whether EN1 expression is a common characteristic
of all fibroblasts or whether it is rather restricted to a fibroblast
subpopulation in SSc, we performed multiplexed IMC from
paired biopsies from ventral and dorsal skin of SSc patients
(Fig. 2 A). We designed and validated a 22-plex panel for IMC
that comprises well-characterized fibroblast markers such as
P4Hβ, platelet-derived growth factor receptor α (PDGFRα),
αSMA, fibroblast activation protein (FAP), FSP-1, Thy1, DPP4,
and Cdh-11, allowing simultaneous identification of multiple fi-
broblast subpopulations. We used image segmentation algo-
rithms to generate cell masks (Fig. 2 A), which allowed
extraction of high-dimensional single-cell data of marker ex-
pression. Subsequent clustering using the Phenograph algo-
rithm identified 11 cellular clusters (Fig. 2 B). EN1 was expressed
at various levels in all clusters, with the highest expression (>1
SD above the mean) in clusters 6 and 7 and the lowest expression
in clusters 1 and 4 (Fig. 2, C and D). Clusters 6 and 7 also showed
particularly high expression of αSMA as the typical myofibro-
blast marker (Fig. 2, D–H). Cluster 6 identifies a subpopulation
with high expression of most fibroblast markers, but also of
CD31/von Willebrand factor and with a particular perivascular
localization, suggestive of cells that may have undergone endo-
thelial-to-mesenchymal transition (Fig. 2, D–H). Other clusters
that express EN1 at intermediate levels are characterized by
marker expression of different fibroblast subpopulations: cluster
8 predominantly expresses Cdh-11; clusters 9 and 10 highly ex-
press FAP; and cluster 5 expresses FSP-1 (Fig. 2 D). EN1 ex-
pression was similar in dorsal and ventral skin, but clusters 6
and 7 were underrepresented and cluster 9 was nearly absent in
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Figure 1. EN1 expression is up-regulated in fibrotic skin. (A) Representative immunofluorescence stainings for EN1 (green) and costainings with P4H (red)
and CD45 (magenta) in the dermis of healthy donors and SSc patients at 1,000-fold magnification (scale bars = 20 µm). Hematoxylin and eosin stainings (200-
fold magnification, scale bars = 100 µm), Voronoi diagrams, and percentages of EN1-positive fibroblasts from all fibroblasts (defined as P4H+CD45− cells) are
included. Data are shown from one experiment (n ≥ 4). (B and C) EN1 mRNA (B) and EN1 intracellular or secreted protein levels (C) in cultured fibroblasts or
their supernatants from healthy donors and SSc patients. Representative Western blot images and quantifications are included (C). Data are shown from one
experiment (n = 3). (D and E) En1 protein levels in the skin of mice challengedwith bleomycin (D) or Tsk-1 mice (E) and their respective controls. Representative
Western blot images and quantifications are included. Data are compiled from two independent experiments (n ≥ 4). (F and G) Representative
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ventral skin (Fig. S1, D–F). In contrast, cluster 8, expressing EN1
at intermediate levels, was overrepresented in ventral skin (Fig.
S1, D–F).
TGFβ signaling induces EN1 expression in a SMAD3-dependent
manner
SSc fibroblasts are characterized by persistent up-regulation of
TGFβ signaling under culture conditions. Considering the up-
regulation of EN1 in cultured SSc fibroblasts, as well as in SSc
patients and different mouse models of skin fibrosis, we hy-
pothesized that TGFβ may reactivate the expression of EN1 in
SSc skin. Indeed, stimulation of cultured fibroblasts with re-
combinant TGFβ induced a persistent up-regulation of EN1
protein levels (Fig. 3 A). In murine skin, activation of TGFβ
signaling by overexpression of a constitutively active TGFβ
receptor type I (TBRICA) increased the protein levels of En1 and
induced the expression of En1 in dermal fibroblasts (Vimentin+,
CD45− cells; Fig. 3, B and C). Inhibition of TGFβ signaling by
treatment with the selective TBRI inhibitor SD-208 prevented
the up-regulation of En1 in bleomycin-induced skin fibrosis and
in fibrotic skin of Tsk-1 mice, further highlighting that TGFβ is
required for the up-regulation of En1 in fibrotic conditions (Fig. 3, D
and E). The stimulatory effect of TGFβ on EN1 expression is SMAD3-
dependent, as siRNA-mediated knockdown of SMAD3 abrogated the
induction of EN1 by TGFβ in vitro (Fig. 3 F). In vivo, inhibition of
canonical TGFβ signaling by Smad3 siRNA prevented En1 up-
regulation in the skin of TBRICA- and bleomycin-challenged mice,
confirming the Smad3 dependence of the TGFβ-induced En1 up-
regulation (Fig. 3, G and H). In silico analysis of the EN1 promoter
revealed two SMAD3 binding sites. ChIP PCR confirmed enhanced
binding of SMAD3 to both predicted SMAD3-binding sites in the EN1
promoter upon TGFβ stimulation (Fig. 3 I).
EN1 promotes fibroblast activation and collagen production
We next analyzed whether EN1 can regulate fibroblast activa-
tion. siRNA-mediated knockdown of EN1 in adult human dermal
fibroblasts rendered them less sensitive to the profibrotic effects
of TGFβ, with lower levels of COL1A1 and COL1A2 mRNA, and
reduced release of collagen protein (compared with non-
targeting siRNA–treated fibroblasts; Fig. 4, A and B). Moreover,
EN1 knockdown prevented TGFβ-induced fibroblast-to-myofi-
broblast transition, with reduced levels of ACTA2 mRNA and
αSMA protein and impaired stress fiber formation (Fig. 4, C–E).
En1fl/flmurine fibroblasts transduced with AdCre (En1-knockout
fibroblasts) released less collagen and expressed lower levels
of myofibroblast markers in response to TGFβ than AdLacZ-
transduced controls (with unaltered expression of En1; Fig. S2).
Overexpression of EN1 in human fibroblasts fostered TGFβ-
induced fibroblast activation with higher levels of COL1A1 and
COL1A2 mRNA and collagen protein and increased levels of
ACTA2 mRNA and αSMA protein and enhanced formation of
stress fibers (Fig. 4, F–J). EN1 overexpression also enhanced the
profibrotic effects of IL-11, IL-13, and connective tissue growth
factor (CTGF) on deposition of fibronectin and collagen type I,
expression of αSMA, and formation of stress fibers, but to a
much lesser extent than the effects of TGFβ (Fig. S3).
EN1 induces a profibrotic profile of gene expression by
modulation of SP binding to the promoters of
profibrotic genes
To evaluate whether EN1 induces transcriptomic changes to
promote fibroblast activation, we performed RNA sequencing
(RNA-seq) from adult human dermal fibroblasts with knock-
down of EN1. We identified 632 high-confidence differentially
expressed genes (EN1-DEGs; 239 down-regulated and 315 up-
regulated) between TGFβ-stimulated fibroblasts with siRNA-
induced EN1 knockdown and TGFβ-stimulated fibroblasts
transfected with nontargeting siRNA (Fig. 5 A). gProfiler en-
richment analysis of the EN1-DEGs revealed enrichment of
multiple gene ontology (GO) and Reactome terms related to ECM
production and organization (such as collagen formation or ECM
organization), cytoskeleton organization (such as microtubule
cytoskeleton organization or cytoskeleton), and Rho GTPases
activity (such as signaling by Rho GTPases), confirming the
functional relevance of EN1-regulated gene expression for TGFβ-
induced fibroblast activation (Fig. 5 B). Gene set enrichment
analysis (GSEA) revealed that EN1 expression levels did not in-
fluence apoptosis-related gene sets (Fig. 5 C).
We next performed in silico transcription factor profiling of
the promoters of EN1-DEGs. We screened the promoter regions
of all EN1-DEGs for potential binding sites against all available
human transcription factor matrices (Table S4). Of note, we did
not identify statistically enriched EN1-binding sites in EN1-DEGs
(Table S4), indicating that EN1 may rather indirectly regulate
gene expression in TGFβ-stimulated fibroblasts via modulation
of the transcriptional activity of other transcription factors.
We found, in particular, members of the SP subfamily of
C2H2 zinc finger transcription factors to be enriched in EN1-
DEGs, with more than twofold increases of binding motifs for
SP1, SP2, SP3, and SP8 as compared with the mean of two ran-
domly generated gene sets as negative controls (Fig. S4 A).
Coimmunoprecipitation experiments demonstrated that TGFβ
promotes interaction of EN1 with SP1, providing experimental
validation for the in silico model of EN1-mediated transcrip-
tional regulation (Fig. 5 E). Although more common in up-
regulated EN1-DEGs, SP1-, SP2-, SP3-, and SP8-binding motifs
were present in the promoters of up- and down-regulated EN1-
DEGs, suggesting that recruitment of additional transcriptional
immunofluorescence stainings for EN1 (green) and costainings with Vimentin (red) and CD45 (magenta) in the dermis of mice challenged with bleomycin and
their controls at 1,000-fold magnification (F; scale bars = 20 µm) and in the hypodermis of Tsk-1 mice and their controls, respectively, at 1,000-fold mag-
nification (G; scale bars = 20 µm). Hematoxylin and eosin stainings (100-fold magnification, scale bars = 200 µm [F] and 40-fold magnification, scale bars = 500
µm [G]), Voronoi diagrams, and percentages of EN1-positive fibroblasts from all fibroblasts (defined as Vimentin+CD45− cells) are included. Data are shown
from one experiment each (n ≥ 3). All data are represented as median ± interquartile range. P values are expressed as follows: *, 0.05 > P > 0.01 (Mann-Whitney
U test).
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Figure 2. EN1 is expressed in multiple fibroblast subpopulations in the skin of SSc patients. (A) Schematic representation of the experimental and
analytical workflow. IMC was performed on paired skin biopsies from ventral and dorsal skin from four SSc patients stained with a panel consisting of
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regulators may determine the transcriptional outcome of EN1-
SP1/2/3/8 binding (Fig. S4 A).
Further transcription factor coregulation analysis of the
promoters of these EN1-DEGs with SP1-, SP2-, SP3-, and SP8-
binding motifs (EN1-SP-DEGs) revealed a consistent pattern for
all four SP members, with major enrichment of binding sites for
other members of the C2H2 family (in particular, KLF5, 16, and 9
and ZNF263 and 384), as well as for members of the EF family
(E2F4 and E2F6; Table S5). Binding sites for these transcription
factors were found in similar frequencies in up- and down-
regulated EN1-SP-DEGs (Fig. S4 B). Interestingly, we also iden-
tified binding motifs for other transcription factors that were
exclusively present in up- or in down-regulated genes: binding
motifs for transcription factor AP-2α (TFAP2A)were enriched in
up-regulated EN1-SP-DEGs, indicating that in conditions of in-
creased expression of EN1 recruitment of TFAP2A may promote
transcriptional repression; in contrast, binding motifs for nu-
clear transcription factor Y β (NFYB) and for transcription factor
Dp-1 (TFDP1) were exclusively found in down-regulated EN1-SP-
DEGs (Fig. S4 B and Table S5), suggesting that their recruitment
may promote transcriptional activation.
Functional analysis of the EN1-SP-DEGs and EN1-SP-DEGs
with binding motifs for other C2H2 transcription factors revealed
major enrichment of processes related to fibroblast activation, in
particular of those pertaining to cytoskeleton organization and
Rho GTPases activity (Fig. 5 D and Table S6).
EN1 ChIP-seq showed binding of EN1 predominantly to in-
tergenic and intronic regions, while SP1 ChIP-seq revealed
binding of SP1 predominantly to promoter regions in all three
biological replicates (Fig. 6 A). SP1 ChIP-seq demonstrated that
knockdown of EN1 significantly decreases the genomic binding
of SP1, with reduced peak counts and reduced activity of SP1 in
peaks (Fig. 6, B and C). From the few genes with EN1 binding in
promoter regions, only the following genes were shared among
all three biological replicates: ROCK1P1, DUX4, and PACSIN2. Of
note, all of these genes also showed binding of SP1 in their
promoter region. We found no direct binding of EN1 to the
promoters of EN1-DEGs; instead, we found binding of SP1 to the
promoter of multiple EN1-DEGs, especially to the down-
regulated EN1-DEGs. gProfiler enrichment analysis of the EN1-
DEGs with direct binding of SP1 revealed enrichment of multiple
GO and Reactome terms related to fibrosis such as cytoskeleton,
microtubule, and signaling by Rho GTPases (Fig. 6 D).
EN1 promotes rearrangements of the microtubule-actin
cytoskeleton in a ROCK-dependent manner to induce
fibroblast activation
GSEA showed negative enrichment scores (“de-enrichment”) for
the GO gene sets regulation of actin nucleation and microtubule
depolymerization in EN1-knockdown fibroblasts stimulated with
TGFβ, suggesting that EN1 might induce myofibroblast differ-
entiation by promoting microtubule-dependent cytoskeletal re-
arrangements (Fig. 7 A).
Microtubule depolymerization induces stress fiber assembly
at focal adhesions and promotes cell contraction (Liu et al., 1998;
Ng et al., 2014). To experimentally validate an EN1-dependent
regulation of microtubules in fibroblasts, we analyzed the mi-
crotubule polymerization state in human dermal fibroblasts
with overexpression or knockdown of EN1 by two methods:
Western blot for insoluble and soluble tubulin and a previously
described tubulin polymerization high-content imaging assay
(Sum et al., 2014). Overexpression of EN1 promotes depolymer-
ization of themicrotubular network, with reduced tubulin intensity
on immunofluorescence stainings and decreased insoluble/soluble
tubulin ratio on Western blot (Fig. 7, B and C). In contrast, knock-
down of EN1 enhanced the formation of microtubular networks,
with increased tubulin intensity and higher insoluble/soluble tu-
bulin ratio (Fig. S5, A and B). Incubation with paclitaxel, a stabilizer
of microtubules, phenocopied the stimulatory effects of EN1
knockdown and prevented the inhibitory effects of EN1 over-
expression on microtubule polymerization (Fig. S5, A and B;
and Fig. 7, B and C). In contrast, vinblastine, an inhibitor of
microtubule polymerization, abrogated the stimulatory effects
of EN1 knockdown on microtubule elongation (Fig. S5, A and B).
We next tested whether EN1 might regulate stress fiber for-
mation and myofibroblast differentiation by modulation of the
microtubular network. Indeed, microtubule stabilization by
paclitaxel abrogated myofibroblast differentiation induced by
EN1 overexpression, with reduced collagen production, αSMA
expression, and stress fiber formation in fibroblasts from stan-
dard 2D culture (Fig. 7, D–H). Moreover, microtubule stabiliza-
tion with paclitaxel prevented the profibrotic effects of EN1 on
3D full-thickness skin equivalents, with lower levels of COL1A1
and ACTA2mRNA, decreased myofibroblast counts, and reduced
thickening of the dermal portion of the skin equivalents com-
pared with vehicle-treated controls (Fig. 9). In contrast, micro-
tubule depolymerization by vinblastine abrogated the inhibitory
effects of EN1 knockdown on TGFβ-induced fibroblast-to-myo-
fibroblast transition (Fig. S5, C–G).
De-enriched GO and Reactome terms also included signaling
by Rho GTPases and Rho GTPase effectors (Fig. 8 A). The activity
of Rho GTPases and of one of their downstream effectors, ROCK,
plays a critical role in regulation of the cytoskeleton (Chang
et al., 2008; Krendel et al., 2002). We thus hypothesized that
EN1 may induce ROCK activity by depolymerizing microtubules
to promote stress fiber assembly and fibroblast activation. In-
deed, knockdown of EN1 prevented the stimulatory effects of
TGFβ on ROCK activity, whereas overexpression of EN1 increased
22 metal-labeled antibodies. Segmentation of the multiplexed images comprising the signals from all markers into masks representing single cells was
performed. (B) Phenograph clustering and visualization on a tSNE map of CD45− E-Cadherin− cells from all patients, regardless of biopsy location. (C) Ex-
pression of EN1 (as log[normalized intensity]) across the clusters. (D) Heatmap of marker expression across the clusters (as Z-score). (E and F) Representative
hematoxylin and eosin staining (E) and schematic representation of clusters 6 and 7 (as the clusters with the highest expression of EN1, >1 SD above the mean;
F), illustrating the spatial relationships of cells belonging to these clusters (scale bars = 200 µm). (G and H) Visualization of the area of interest marked in F, with
EN1 signals (green) and αSMA (G) or CD31 and von Willebrand factor (H; red) as the markers with the highest expression from the clusters 6 and 7 (scale bars =
50 µm). Data were obtained from n = 8 biological samples from 4 SSc patients (paired ventral and dorsal biopsies) from one experiment.
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Figure 3. TGFβ up-regulates EN1 in a SMAD3-dependent manner. (A) EN1 protein levels in cultured human fibroblasts at 1, 3, 6, 24, and 48 h after TGFβ
stimulation. Representative Western blot images and quantification are included. Data are compiled from two experiments (n ≥ 4). (B) En1 protein levels in the
skin of mice expressing TBRICA and their controls. Representative Western blot images and quantifications are included. Data are compiled from two
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ROCK activity at baseline and in response to TGFβ (Fig. 8, B and C).
Stabilization of microtubules with paclitaxel prevented the in-
duction of ROCK activity by EN1, highlighting that microtubule
depolymerization is required for EN1 to induce ROCK activity
(Fig. 8 C). Moreover, the selective ROCK inhibitor Y27632 pre-
vented EN1-induced myofibroblast differentiation, stress fiber
formation, and fibrotic transformation of 3D full-thickness skin
equivalents (Fig. 8, D–H; and Fig. 9). Thus, EN1 promotes depo-
lymerization of microtubules to induce ROCK activity, which
facilitates TGFβ-induced stress fiber formation, myofibroblast
differentiation, and collagen deposition.
Knockout of En1 ameliorates experimental skin fibrosis
To analyze whether knockout of En1 reduces fibroblast activa-
tion in vivo and protects from experimental fibrosis, we gen-
erated En1fl/fl × Col6Cremice, with fibroblast-specific constitutive
En1 knockout. Mice with selective depletion of En1 in fibroblasts
did not show a basic phenotype in the absence of profibrotic
stimuli as compared with controls, and their dermal structure
was preserved (Fig. 10). We employed three complementary
models of skin fibrosis: (1) the TBRICA model; (2) the bleomycin-
induced model; and (3) the Tsk-1 model. Skin fibrosis was
strongly ameliorated in mice with fibroblast-specific knockout
of En1 in comparison with control mice in all three models, with
reduced dermal or hypodermal thickness, lower myofibroblast
counts, and reduced hydroxyproline content (Fig. 10, A–L).
Discussion
A landmark study by Rinkevich et al. (2015) and a follow up
study by Jiang et al. (2018) showed that a subpopulation of fi-
broblasts transiently express En1 during skin development in
murine embryos. The number of En1-positive fibroblasts in-
creases during embryonic development, but these cells silence
the expression of En1 before birth under homeostatic conditions
(Jiang et al., 2018). However, the regulation of En1 expression
was not investigated in these studies. Here, we demonstrate that
EN1 expression is up-regulated in fibrotic skin of SSc patients
compared with skin from healthy donors, as well as in three
different murine models of skin fibrosis. Multiple fibroblast
subpopulations express EN1 in adult skin of SSc patients, in
particular fibroblast subpopulations with high expression of
αSMA. A previous study evaluated the expression of EN1 in adult
human skin by immunohistochemistry (Miura et al., 2018).
Although not specifically followed up by the authors, EN1-
positive single cells can be observed in the dermis, suggesting
that, in line with our results, adult fibroblasts in human skin can
express EN1. In contrast to the redundant expression of EN1 and
EN2 in dopaminergic neurons (Hanks et al., 1995), the low ex-
pression of EN2 in adult skin and the lack of induction in fibrotic
skin excluded a major role of EN2 in skin fibrosis.
We demonstrate on multiple experimental levels that ca-
nonical TGFβ signaling reactivates the expression of EN1 in
cultured fibroblasts and fibrotic skin. (1) Stimulation of cultured
dermal fibroblasts with recombinant TGFβ up-regulates the
intracellular levels of EN1. (2) EN1 levels are increased in SSc
fibroblasts as compared with fibroblasts isolated from healthy
individuals even after several passages in culture. As persistent
activation of TGFβ signaling is a major characteristic of SSc fi-
broblasts, this finding provides indirect evidence for a TGFβ-
dependent regulation of EN1 in SSc. (3) Overexpression of TBRICA
increases En1 protein levels in murine skin, thus confirming that
TGFβ is sufficient to increase the expression levels of En1 in
fibroblasts in vivo. (4) The induction of EN1 by TGFβ is mediated
by canonical TGFβ/SMAD3 signaling, as knockdown of SMAD3
abrogates the stimulatory effects of TGFβ on EN1 expression in
cultured fibroblasts and in murine skin. (5) Selective inhibition
of TGFβ signaling prevented the up-regulation of En1 in
bleomycin-induced and Tsk-1 models of experimental skin fi-
brosis, highlighting that TGFβ signaling is essentially required
for the up-regulation of En1 in fibrotic skin.
However, additional factors other than TGFβ may also pro-
mote the expression of EN1. EN1 has been shown to be a target
of WNT1 in vertebrate midbrain development, and WNT1 is
also up-regulated in multiple fibrotic disorders including SSc
(Akhmetshina et al., 2012; Bergmann and Distler, 2016; Beyer
et al., 2012b; Danielian and McMahon, 1996; Königshoff et al.,
2009). Notch signaling, another stem cell pathway that is hy-
peractive in SSc, is required to maintain the expression of en-
grailed during the development of the ocellar complex in
Drosophila melanogaster (Aguilar-Hidalgo et al., 2013; Beyer and
Distler, 2013; Dees et al., 2011a; Dees et al., 2011b). Finally,
ischemia-reperfusion injury, which may occur as a consequence
of microvascular endothelial dysfunction in SSc, can also induce
EN1 expression and may contribute to its up-regulation in SSc
(Beyer et al., 2009; Villanueva et al., 2006).
In extension of the findings by Rinkevich et al. (2015), we
demonstrate that EN1 not only serves as an embryonic marker
experiments (n ≥ 4). (C) Representative immunofluorescence stainings for En1 (green) and costainings with Vimentin (red) and CD45 (magenta) in the dermis of
mice expressing TBRICA and their controls at 1,000-fold magnification (scale bars = 20 µm). Data are shown from one experiment (n ≥ 4). Hematoxylin and
eosin stainings (100-fold magnification, scale bars = 200 µm), Voronoi diagrams, and percentages of EN1-positive fibroblasts from all fibroblasts (defined as
Vimentin+CD45− cells) are included. (D and E) En1 protein levels in the skin of mice challenged with bleomycin (D) or Tsk-1 mice (E) and/or treated with the
TBRI inhibitor SD-208 and their respective controls. Representative Western blot images and quantifications are included. Data are compiled from two ex-
periments (n ≥ 4). (F) EN1 protein levels in cultured human fibroblasts with siRNA-mediated SMAD3 knockdown with or without stimulation with TGFβ (24 h)
and their controls (fibroblasts transfected with nontargeting siRNA). Representative Western blot images and quantification are included. Data are compiled
from two experiments (n = 4). (G and H) En1 protein levels in the skin of TBRICAmice (or, as controls, mice injected with an adenovirus expressing LacZ; G) or of
mice challenged with bleomycin (or, as controls, mice injected with NaCl; H) and/or treated with SMAD3 siRNA and their controls (mice injected with
nontargeting siRNA). Representative Western blot images and quantifications are included. Data are compiled from two experiments (n = 5). (I) ChIP PCR for
SMAD3 binding at predicted SMAD3 motifs in the promoter of EN1. Data are compiled from two experiments (n = 4). All data are represented as median ±
interquartile range. P values are expressed as follows: *, 0.05 > P > 0.01; **, 0.01 > P > 0.001; ***, P < 0.001 (Mann–Whitney U test for B and C; ANOVA with
Tukey’s post hoc test for A and D–I).
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Figure 4. EN1 promotes fibroblast activation and collagen production. (A–E) siRNA-mediated knockdown of EN1 prevents TGFβ-induced fibroblast
activation. Relative mRNA levels of COL1A1 and COL1A2 (A). Relative protein levels of secreted collagen type I (B). Relative mRNA levels of ACTA2 (C). Rep-
resentative immunofluorescence stainings for αSMA (D) and stress fibers (E) at 400-fold magnification (scale bars = 50 µm). Quantification of average signal
intensity for each cell (relative to control) is included. Data for A–E were obtained from n ≥ 4 independent biological samples per group from two independent
experiments. (F–J) EN1 overexpression promotes fibroblast activation. Relative mRNA levels of COL1A1 and COL1A2 (F). Relative protein levels of secreted
collagen type I (G). Relative mRNA levels of ACTA2 (H). Data for F–J were obtained from n ≥ 4 independent biological samples per group from two independent
experiments. Representative immunofluorescence stainings for αSMA (I) and stress fibers (J) at 400-fold magnification (scale bars = 50 µm). Quantification of
average signal intensity for each cell (relative to control) is included. All data are represented as median ± interquartile range. P values are expressed as follows:
*, 0.05 > P > 0.01; **, 0.01 > P > 0.001; ***, P < 0.001 (ANOVA with Tukey’s post hoc test).
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Figure 5. EN1 induces a profibrotic gene expression profile. (A–C) RNA-seq results showing that knockdown of EN1 partially reverses the profibrotic gene
expression profile induced by TGFβ, without affecting apoptosis. Heatmap of expression levels of the 632 EN1-DEGs across the three replicates for each
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for a defined population of fibroblasts with a high capacity to
produce ECM proteins, but EN1 also regulates the activation
status of adult human dermal fibroblasts. EN1-deficient fibro-
blasts are less sensitive to TGFβ-induced activation, whereas
forced overexpression of EN1 renders fibroblasts more suscep-
tible to the profibrotic effects of TGFβ and, to a lesser extent,
to those of other profibrotic molecules such as IL-11, IL-13,
and CTGF (Ng et al., 2019; Schafer et al., 2017), with increased
myofibroblast differentiation and enhanced collagen release.
Moreover, EN1 overexpression induces myofibroblast differen-
tiation in the absence of external profibrotic stimuli. EN1 is thus
both necessary to fully mount the fibroblast response to profi-
brotic stimuli (in particular to TGFβ) and also sufficient to induce
fibroblast activation in the absence of external stimuli.
Selective depletion of En1 in fibroblasts also reduced the
profibrotic effects of TGFβ signaling in vivo. Mice with fibroblast-
specific knockout of En1 were protected from experimental fi-
brosis induced by overexpression of a constitutively active TGFβ
receptor type I. Fibroblast-specific depletion of En1 also ame-
liorated skin fibrosis in Tsk-1 mice and mice challenged with
bleomycin. Lineage commitment of En1-expressing fibroblasts
seemed to be unaffected in mice with fibroblast-specific En1
knockout, since the structure and collagen composition of their
dermis were comparable to those of littermates with unaltered
En1 expression. Although the frequency of recombination in
Col6Cre transgenic mice is almost absent in nonmesenchymal
cells (Armaka et al., 2008), Col6Cre-induced recombination is
less specific to fibroblasts than in, for example, PDGFRα-Cre
(Horikawa et al., 2015). Despite this limitation of our study, the
strong in vitro effects on fibroblast activation suggest that EN1 up-
regulation and aberrant signaling in fibroblasts play a pivotal role
in skin fibrosis.
RNA-seq of adult human dermal fibroblasts with siRNA-
mediated knockdown of EN1 combined with functional ex-
periments demonstrated that EN1 induces depolymerization
of microtubules with a decreased ratio of insoluble to soluble
tubulin. Disruption of the microtubule network promotes
formation and maturation of focal adhesions in a ROCK-
dependent manner, stimulating the assembly of actin stress
fibers (Bershadsky et al., 1996; Liu et al., 1998; Ng et al., 2014),
which is required to promote fibroblast-to-myofibroblast
differentiation (Dugina et al., 2001; Hinz et al., 2003). Phar-
macologic stabilization of microtubules or inhibition of ROCK
prevents EN1-induced fibroblast-to-myofibroblast transition
and collagen release in both standard 2D fibroblast cultures
and 3D full-thickness skin equivalents. In contrast, pharma-
cologically induced microtubule depolymerization abrogates
the antifibrotic effects of EN1 knockdown. These data unravel
a novel mechanism of regulation of cytoskeletal organization
during fibroblast-to-myofibroblast differentiation in fibrotic
diseases.
Mechanistically, the effects of EN1 on cytoskeleton and ROCK
activity are not mediated by direct binding to EN1 motifs in EN1-
DEGs, but by trans-regulation, i.e., by modulating the activity/
binding of SP family members of transcription factors. ChIP-seq
experiments for EN1 and SP1, the SP member with the most
predicted binding motifs in the EN1-DEGs, showed that EN1
predominantly binds to intergenic and intronic regions, while
SP1 predominantly binds to promoter regions. Our results are in
line with previous EN1 ChIP-seq data from triple-negative breast
cancers, which also demonstrate predominant binding of EN1 to
noncoding regions (Peluffo et al., 2019). ChIP-seq for EN1 sup-
ports the conclusion that EN1 regulates the binding of SP1 to the
promoter of profibrotic genes related to the microtubule cyto-
skeleton and Rho GTPases. In silico transcription factor profiling
suggests that the profibrotic roles of EN1 are likely mediated by
interference with a network of profibrotic transcription factors
including SP1 (validated by SP1 ChIP-seq), SP2, SP3, SP8, and
other members of the C2H2 family (Córdova et al., 2015; Jiang
et al., 2013; Manabe et al., 2002; Sysa et al., 2009; Verrecchia
et al., 2001). The potent antifibrotic effects of EN1 knockdown
might thus be attributed to the cumulative changes in target
specificity of multiple transcription factors.
In silico transcription factor profiling and functional en-
richment analysis support an EN1-transcriptional regulation of
gene expression with specific functional modularity: EN1-DEGs
with predicted transcriptional regulation by SP family members
(and coregulation by other members of the C2H2 family) are
functionally related to fibroblast activation (in particular to cy-
toskeleton organization and Rho GTPases activity). These data
implicate that EN1 can direct the specificity of SP-containing
regulatory modules toward genes with functional relevance for
fibrosis. Reducing EN1 levels or inhibiting the interaction of EN1
with SP family members may thus interfere with this patho-
logical regulation of gene expression and reestablish the physi-
ological target specificity of SP transcription factors.
Targeted inactivation of EN1, for instance with recently de-
scribed synthetically designed EN1 interference peptides (EN1-
iPep; Beltran et al., 2014; Gandhi et al., 2018; Sorolla et al., 2019)
might thus offer therapeutic potential for the treatment of fi-
brotic diseases such as SSc. Considering the antiapoptotic roles
of EN1 in dopaminergic neurons (Rekaik et al., 2015), a systemic
therapy that targets EN1 may have adverse effects on the central
nervous system. However, in the case of EN1-iPep, occurrence of
condition. Hierarchical clustering of the replicates and of the EN1-DEGs’ expression are included (A). Dot plot showing gene ratio (on the x axis), gene count (as
dot size), and adjusted P value (as color gradient) of selected enriched GO and Reactome terms (after g:Profiler enrichment analysis) related to fibrosis (B).
GSEA of the apoptosis Reactome term (C). Data for A–C were obtained from n = 3 independent biological samples per group. (D) Circular packing plots il-
lustrating enrichment of fibrosis-related GO and Reactome terms (after g:Profiler enrichment analysis) of the EN1-DEGs with predicted binding motifs for SP1/
2/3/8 (SP) and cobinding with other members of the C2H2 or E2F families, or with NFYB (expressed as percentages from the total fibrosis-related processes
enriched in EN1-DEGs). The threshold for DEGs was false discovery rate < 0.25 and fold-change >1.5, and the conditions were as follows: nontargeting siRNA
treated human fibroblasts stimulated with TGFβ as reference group and EN1 siRNA treated human fibroblasts stimulated with TGFβ as treatment group.
(E) Coimmunoprecipitation of EN1 with SP1 in human fibroblasts ± TGFβ (24 h). Representative Western blot images are included. Data were obtained from
two independent experiments (n = 3).
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Figure 6. Direct genomic targets of EN1 and SP1. (A) Genomic localization of EN1 and SP1 peaks showing enrichment of EN1 peaks in intergenic and intronic
regions, while SP1 peaks show great enrichment in promoter regions defined as 300–3,000 bp upstream from transcription start site. (B and C) Knockdown of
EN1 reduces the number and activity of SP1 peaks across all three biological replicates. Number of SP1 peaks (B). Read counts in SP1 peaks (C). (D) Dot plot
showing gene ratio (on the x axis), gene count (as dot size), and adjusted P value (as color gradient) of selected enriched GO and Reactome terms after g:Profiler
enrichment analysis of the EN1-DEGs with direct SP1 binding related to fibrosis. Data were obtained from n = 3 independent biological samples per group.
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Figure 7. EN1 overexpression promotes microtubule depolymerization to induce myofibroblast differentiation. (A) GSEA of the indicated GO terms,
showing that EN1 knockdown de-enriches genes related to microtubule depolymerization and actin nucleation. (B and C) EN1 overexpression induces mi-
crotubule depolymerization. Representative immunofluorescence stainings for α-Tubulin at 400-fold magnification (scale bars = 50 µm). Quantification of total
signal intensity for each cell (relative to control) is included (B). Protein levels of soluble and insoluble α-Tubulin. Representative Western blot images and
Györfi et al. Journal of Experimental Medicine 13 of 23




























































































major nervous system toxicity should be hindered by several
factors: (1) the low diffusibility of EN1-iPep through the blood–
brain barrier; (2) the C-terminal RGD domain of EN1-iPep
(Sorolla et al., 2019) that increases the specificity for cells with
high expression of integrin αv, such as fibroblasts (Margadant
and Sonnenberg, 2010); and (3) the selective targeting of EN1,
since EN2 can functionally substitute EN1 in the dopaminergic
neurons. However, further studies would be required to test the
efficacy and safety of targeting EN1 in fibrotic diseases.
In summary, we demonstrate that EN1, beyond its function as
an embryonic marker for a population of metabolically active
fibroblasts during embryonic development, is also expressed by
multiple fibroblast subpopulations in the skin of SSc patients
and functionally regulates fibroblast-to-myofibroblast transition
in adult skin. EN1 interacts with SP1 (and presumably other
members of the SP/C2H2 family of transcription factors) upon
stimulation with TGFβ and enhances its binding to the promoter
of profibrotic genes related to the microtubule cytoskeleton and
Rho GTPases to promote depolymerization of microtubules. This
induces stress fiber formation, myofibroblast differentiation,
and collagen release in a ROCK-dependent manner. In contrast,
EN1-deficient fibroblasts are less sensitive to the profibrotic
effects of TGFβ. Moreover, fibroblast-specific knockout of En1
ameliorates experimental skin fibrosis in several complemen-
tary models. As EN1 is up-regulated in fibrotic diseases in a
TGFβ-dependent manner, it functions as a molecular amplifier
of TGFβ signaling and TGFβ-induced fibroblast differentiation.
Targeted inactivation of EN1 may thus offer potential to inhibit
TGFβ signaling and fibroblast activation in fibrotic diseases.
Materials and methods
Patient samples
Skin biopsies from 10 SSc patients and 10 age- and sex-matched
healthy volunteers were used for staining or fibroblast isolation.
Skin biopsies from SSc patients were taken from the affected
skin of the forearm. All patients fulfilled the American College of
Rheumatology/European League Against Rheumatism 2013 criteria
(van denHoogen et al., 2013). Seven patientswere female, and three
weremale. Themedian age of SSc patients was 44 yr (range 19–65),
and median disease duration was 5 yr (range 1–12). Further clinical
data are provided in Table S2. The human studieswere approved by
the ethics committee of the Medical Faculty of the University of
Erlangen-Nuremberg. All patients and controls signed a consent
form approved by the local institutional review board.
Animal studies
Mice carrying two conditional alleles of En1 (En1fl/fl), En1tm8.1Alj/J
(stock no. #007918, The Jackson Laboratory; Sgaier et al., 2007),
were crossbred with Col6Cre mice, B6.Cg-Tg(Col6a1-cre)1Gkl/
Flmg (obtained from G. Kollias, Institute of Immunology, Bio-
medical Sciences Research Center “Alexander Fleming,” Vari,
Greece; Armaka et al., 2008). For all mouse experiments, for
En1fl/fl × Col6Cre mice with fibroblast-specific knockout of En1,
En1fl/fl × wt/wt littermates without Cre-mediated recombination
were used as controls. The role of EN1 signaling in fibrosis was
investigated in three different mouse models: (1) In the model of
bleomycin-induced dermal fibrosis, fibrosis was induced by
subcutaneous injections of bleomycin (50 µg) every other day
for 4 wk starting at age 6 wk (Dees et al., 2015; Soare et al., 2016).
Littermates injectedwith 0.9%NaCl served as controls. (2) In the
TBRICA skin fibrosis model, fibrosis was induced by subcuta-
neous injections of replication-deficient type 5 adenoviruses
(6.67 × 107 viral particles/administration/mouse) encoding for a
constitutively active TBRI construct every second week (Beyer
et al., 2010). Fibrosis was evaluated after 8 wk. Mice injected
with type 5 adenoviruses encoding for LacZ served as controls.
(3) Tsk-1 mice are a genetic model of skin fibrosis with pro-
gressive accumulation of ECM in the hypodermal layer of the
skin (Beyer et al., 2010). Tsk-1 mice, B6.Cg-Fbn1Tsk/J (stock no.
#014632, The Jackson Laboratory; Siracusa et al., 1996) were
analyzed at an age of 10 wk (Beyer et al., 2012a). En1fl/fl × Col6Cre ×
wt/wt littermates were used as healthy controls. All animal
experiments were approved by the government of Unterfranken
in Würzburg, Germany.
Histological analyses
Skin sections were stained with hematoxylin and eosin or tri-
chrome. Dermal or hypodermal thickness was analyzed in three
consecutive skin sections from each mouse at four different
sites/section in a blinded manner, as described (Akhmetshina
et al., 2012). Pictures were taken at 40- or 100-foldmagnification
with a Nikon Eclipse 80i microscope. Immunohistochemistry
staining using αSMA antibody (1:1,000, #A5228; Sigma-Aldrich)
and goat anti-mouse HRP-conjugated secondary antibody (1:5,000,
#P0447; Dako) was performed for the visualization and quantifi-
cation of myofibroblast numbers in murine skin.
Cell culture
Human and murine fibroblasts were isolated and cultured as
described previously (Chakraborty et al., 2017; Palumbo-Zerr
et al., 2015). In healthy human dermal fibroblasts, EN1 over-
expression was induced by transfection of 0.5 µg of plasmid
encoding the human EN1 (Origene). Knockdown of EN1 or of
SMAD3 was induced by transfection of 3 µg of EN1-targeting
or SMAD3-targeting siRNA using an Amaxa 4D-Nucleofector.
Healthy dermal fibroblasts transfected with an equal amount
of empty vector or nontargeting siRNA served as controls. In
quantification of insoluble/soluble α-Tubulin ratio are included (C). Data for B and C were obtained from two independent experiments (n ≥ 4).
(D–H) Pharmacological stabilization of microtubules prevents EN1-induced myofibroblast differentiation. Relative mRNA levels of COL1A1 (D). Relative
protein levels of secreted collagen type I (E). Relative mRNA levels of ACTA2 (F). Representative immunofluorescence stainings for αSMA (G) and stress fibers
(H) at 400-fold magnification (scale bars = 50 µm). Quantification of average signal intensity for each cell (relative to control) is included. Data for D–H were
obtained from two independent experiments (n ≥ 4). All data are represented as median ± interquartile range. P values are expressed as follows: *, 0.05 > P >
0.01; **, 0.01 > P > 0.001; ***, P < 0.001 (ANOVA with Tukey’s post hoc test).
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Figure 8. EN1 induces ROCK activity to coordinatemicrotubule-actin cytoskeletal rearrangements andmyofibroblast differentiation. (A) GSEA of the
indicated Reactome terms, showing that EN1 knockdown de-enriches genes related to signaling by Rho GTPases and Rho GTPases effectors. (B and C) EN1
induces ROCK activity by depolymerizing microtubules. ROCK activity after EN1 knockdown (B). ROCK activity after EN1 overexpression with/without
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murine fibroblasts isolated from En1fl/fl mice, Cre-mediated
recombination was induced by infection with type 5 adenovi-
ral vectors encoding for Cre recombinase at a multiplicity of
infection of 80 (Palumbo-Zerr et al., 2017). Type 5 adenoviral
vectors encoding for LacZ served as controls. In selective ex-
periments, cells were stimulated with recombinant TGFβ (10 ng/
ml; PeproTech) for 24 h, unless stated otherwise. In certain ex-
periments, microtubules were stabilized by addition of paclitaxel
(1 µM); depolymerized by addition of vinblastine (1 µM); or ac-
tivity of Rho kinase 1 and 2 was inhibited by Y27632 (1 µM).
3D full-thickness skin equivalents
3D full-thickness skin equivalents were generated with human
fibroblasts transfected with 0.5 µg of plasmid encoding for EN1
or a CMV control vector. After transfection, fibroblasts (4 × 105
cells for each replicate) were suspended in neutralization solu-
tion (232.5 ml DMEM/F12, 7.5 ml FBS, 7.5 ml 3 M HEPES, and
2.5 ml chondroitin sulfate) and mixed with rat tail collagen type
1 (10 mg/ml). 500 µl of neutralized fibroblast–containing colla-
gen (2 parts of collagen to 1 part neutralization solution con-
taining fibroblasts) was added in each cell-culture insert with
porous membranes (8 µm; Greiner Bio One), to create the
dermal-like part. The dermal components were cultured for 1 d
in DMEM supplemented with 10% FBS, 1% penicillin/strepto-
mycin at 37°C, 5% CO2, and atmospheric O2. The epidermal
component was generated by seeding 5 × 105 normal human
epidermal keratinocytes for each replicate resuspended in Epi-
life medium with 1% human keratinocyte growth supplement
(Gibco BRL) and with extra 1.44 mM CaCl2 on the apical surface
of the dermal components on the following day. 1 d later, the
full-thickness skin models were cultured in Epilife medium
supplemented with 1% human keratinocyte growth supplement
(Gibco BRL), 1.44 mM CaCl2, 0.125 mM L-ascorbic acid
2-phosphate, and 10 ng/ml keratinocyte growth factor (Sigma-
Aldrich) at an air-liquid interface and treated with paclitaxel
(1 µM) or Y27632 (1 µM).
RNA-seq
Total RNA from EN1-knockdown and control human fibro-
blasts stimulated with TGFβ (with three biological replicates per
condition) was extracted as described (Wohlfahrt et al., 2019).
RNA-seq was performed by Novogene (Cambridge, UK) on an
Illumina NovaSeq platform using a paired-end 150-bp sequenc-
ing strategy. Read counts were normalized by trimmed mean of
M values method for analysis with edgeR and limma-voom. For
analysis with DESeq2, the internal normalization method listed
on the package was used (Fuchs et al., 2020). Differential gene
expression analysis was performed using edgeR, limma-voom,
and DESeq2 R packages, with the following thresholds for
differential expression: Benjamini–Hochberg adjusted P value/
false discovery rate <0.25 and fold-change >1.5. Genes that were
identified as differentially expressed by at least two of the three
methods were defined as high-confidence DEGs and used for
downstream analyses. Heatmaps were generated using pheat-
map package. Dot plots were generated with ggplot2 R package.
Functional enrichment analysis was performed using the g:
Profiler web tool with a threshold of 0.05 for adjusted P values
using the GO, Reactome, KEGG, and Wiki Pathways databases
(Raudvere et al., 2019). Gene ratios of selected GO or Reactome
terms were plotted as dot plots. GSEA was performed using
GSEA software v3.0 (Broad Institute) with previously curated
gene sets from the Molecular Signatures Database and a threshold
of 0.25 for false discovery rate–corrected q value (Subramanian
et al., 2005). The RNA-seq datasets were deposited in the GEO
database (accession no. GSE174598).
In silico analysis of the promoters of DEGs
Flanking regions (−800) of up- and down-regulated DEGs were
retrieved from Ensembl database (GRCh38.p13). Negative con-
trol sequences of the same length were generated with random
ACTG dummy sequences using Perl. Transcription factor pro-
filing analysis against all human matrices extracted from JAS-
PAR2018 database was performed with sequence scanning from
TFBStools package v1.26.0 (Tan and Lenhard, 2016) using R
version 4.0.0. The top 1% of results sorted by calculated binding
scores was used for further analysis. Transcription factor en-
richment was calculated by the ratio of genes predicted for one
transcription factor relative to the total number of up- and
down-regulated genes used in the analysis. Transcription factors
with >20% promotor binding were selected as significant.
Functional analysis was performed using g:Profiler web tool
(Raudvere et al., 2019). Results of the transcription factor
analysis are presented in circular packing plots generated with
ggraph package v2.0.3 (https://cran.rstudio.com/web/packages/
ggraph/).
Quantitative real-time PCR
Total RNA was isolated with the NucleoSpin RNA II extraction
system (Macherey-Nagel) and reverse transcribed into cDNA.
Gene expression was quantified by real-time PCR using the
Mx3005P Sequence Detection System (Agilent Technologies).
Primers were designed with Primer3 software and are listed in
Table S1. Samples without enzyme in the reverse transcription
reaction were used as negative controls. Unspecific signals
caused by primer dimers were excluded by nontemplate con-
trols and by dissociation curve analysis. β-Actin was used to
normalize for the amounts of cDNA within each sample. Dif-
ferences were calculated with the threshold cycle (Ct) and the
microtubule stabilization (C). Data for B and C were obtained from two independent experiments (n ≥ 4). (D–H) Pharmacological inhibition of ROCK activity
prevents EN1-induced myofibroblast differentiation. Relative mRNA levels of COL1A1 (D). Relative protein levels of secreted collagen type I (E). Relative mRNA
levels of ACTA2 (F). Representative immunofluorescence stainings for αSMA (G) and stress fibers (H) at 400-fold magnification (scale bars = 50 µm).
Quantification of average signal intensity for each cell (relative to control) is included. Data for D–H were obtained from two independent experiments (n ≥ 4).
All data are represented as median ± interquartile range. P values are expressed as follows: *, 0.05 > P > 0.01; **, 0.01 > P > 0.001; ***, P < 0.001 (ANOVA with
Tukey’s post hoc test).
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comparative Ct method for relative quantification (Dees et al.,
2020).
Western blot analysis
The soluble and insoluble fractions of α-Tubulin were extracted
as described (Sandbo et al., 2013). The total protein concentra-
tion of cell lysates was determined by Bradford assay (#5000001;
Bio-Rad). Proteins were separated by SDS-PAGE and transferred
to a polyvinylidene difluoride membrane. The membrane was
incubated with primary antibodies against EN1 (1:200; Santa
Cruz Biotechnology), β-ACTIN (1:10,000, #A5441; Sigma-Aldrich),
p-SMAD3 (1:1,000, #9520; Cell Signaling), αSMA (1:1,000, #A5228;
Sigma-Aldrich), α-Tubulin (1:1,000, #14-4502-82; Thermo Fisher
Scientific), SP1 (#9389S; Cell Signaling), and HRP-conjugated
Figure 9. EN1 promotes TGFβ-induced fibrotic transformation of 3D skin equivalents in a microtubule- and ROCK-dependent manner. (A–E)
Pharmacological stabilization of microtubules or inhibition of ROCK activity prevents EN1-mediated fibrotic transformation of 3D skin equivalents. Relative
mRNA levels of COL1A1 (A) and ACTA2 (B). Representative trichrome stainings of skin models, acquired with a slide scanner at 40× magnification; adjacent
pictures of the same slide were stitched to generate overview pictures; white bars indicate dermal thickness (scale bars = 200 µm; C). Quantification of dermal
thickness (D) and of myofibroblast counts (E). All data are represented as median ± interquartile range of n = 6 independent biological samples per group from
two independent experiments. P values are expressed as follows: ***, P < 0.001 (ANOVA with Tukey’s post hoc test).
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Figure 10. Fibroblast-specific knockout of En1 ameliorates experimental skin fibrosis. (A–D) TBRICA mice with fibroblast-specific knockout of En1 are
protected from skin fibrosis. Representative trichrome stainings of the skin shown at 100× magnification (scale bars = 200 µm; A). Quantification of dermal
thickness (B), myofibroblast counts (C), and hydroxyproline content (D), with figure legend under the plots. (E–H) Bleomycin-challenged mice with fibroblast-
specific knockout of En1 are protected from skin fibrosis. Representative trichrome stainings of the skin shown at 100× magnification (scale bars = 200 µm; E).
Quantification of dermal thickness (F), myofibroblast counts (G), and hydroxyproline content (H), with figure legend under the plots. (I–L) Tsk-1 mice with
fibroblast-specific knockout of En1 are protected from skin fibrosis. Representative trichrome stainings of the skin shown at 40× magnification (I).
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secondary antibodies (1:5,000; Dako). Blots were visualized by
ECL. β-Actin was used as loading control. Western blots were
quantified using ImageJ software.
Coimmunoprecipitation
Fibroblasts were collected in lysis buffer, as for Western blot.
10% of the amount of protein used for immunoprecipitation was
used as input. Cell extracts were incubated with 30 µl protein
A/G Sepharose and 5 µg of either SP1 or rabbit IgG antibody
(#9389S; Cell Signaling; and #NI01; Millipore). Unbound proteins
were removed by washing with lysis buffer. Sepharose-bound
protein complexes were separated via SDS-PAGE followed by
Western blotting on a polyvinylidene difluoride membrane (see
Western blot analysis).
ChIP PCR and sequencing
ChIP assays, including purification of the enriched DNA, were
performed using the ChIP-IT High Sensitivity Kit (Active Motif).
In brief, 20–30 µg of sonicated chromatin extract was incubated
with 1 µg of antibodies against SMAD3, EN1, or SP1 (SMAD3,
#9523S; SP1, #9389S; both Cell Signaling; EN1, NBP2-57757;
Novus Biologicals) or rabbit IgG antibody (#NI01; Millipore).
SMAD3 binding in EN1 promoter was determined by PCR of the
enriched DNA (after immunoprecipitation with an antibody
against SMAD3) using the following primer pairs: 59-TTCTAT
GGCCTCTGGACGTG-39 (forward) and 59-ACTGTCGCTGAGAGA
TTCGT-39 (reverse) and 59-CTGAGTGTCAGCGCGAGTT-39 (for-
ward) and 59-TTTTGCCTTCAAACCGGAAGC-39 (reverse).
Enriched DNA after immunoprecipitation with antibodies
against EN1 or SP1 from EN1 knockdown and control human fi-
broblasts stimulated with TGFβ (with three biological replicates
per condition) was sequenced by Novogene on an Illumina No-
vaSeq 6000 platform. Alignment to the GRCh37 reference ge-
nome was performed using Bowtie2 software (Langmead and
Salzberg, 2012), and the generated result bam files were sorted
with samtools (Li, 2011) and parsed byMACS v2.2.7.1 (Feng et al.,
2012) for peak calling. Consequently, the results were assessed
by ChIPQC library (Carroll et al., 2014), and peak annotation was
performed using ChIPseeker (Yu et al., 2015). The promoter
regions were then carefully extracted for pairwise comparison
with the differential gene expression results, down- and up-
regulated, respectively. Functional enrichment analysis was
completed using g:Profiler, and figures were plotted using
ggplot2 library. The ChIP-seq datasets were deposited in the
GEO database (accession no. GSE174580).
Quantification of collagen protein
The amount of soluble collagen in cell culture supernatants was
quantified using the SirCol collagen assay (Biocolor). The total
collagen content of skin tissue samples was determined by hy-
droxyproline assay as described previously (Zehender et al.,
2018; Zhang et al., 2017).
ECM staining
ECM staining was performed as described (Chakraborty et al.,
2020). An equal number of fibroblasts (3 × 103/well for 384-well
plates) was seeded in each well of dark-walled imaging plates
(BD Biosciences). After 5 d of incubation with or without stim-
ulation with recombinant TGFβ (10 ng/ml), IL-11 (10 ng/ml), IL-
13 (100 ng/ml), or CTGF (50 ng/ml) at 37°C and 5% CO2, cells
were washed in PBS and lysed with 0.25 M ammonium hy-
droxide in 25mMTris for 3 min at 37°C. Before cell lysis, Preston
Blue staining was performed to account for differences in cell
viability between conditions. The matrix was washed three
times in PBS, fixed using 100% methanol for 30 min at −20°C,
and then stained with anti-Fibronectin Alexa Fluor 488 (1:200;
eBioscience), anti-collagen type I antibody (1:200; Sigma-Aldrich),
and anti-collagen type III (1:200, Millipore). The ECM stainings
were imaged using the CellInsight CX5 High Content Screening
Platform (Thermo Fisher Scientific), and total intensity per well
was automatically quantified using a custom pipeline in HCS
Studio Cell Analysis software, normalized to cell viability, and
represented as a violin plot for each condition using ggplot2.
Immunohistochemistry and immunofluorescence staining
Formalin-fixed, paraffin-embedded skin sections or fibroblasts
fixed in 4% paraformaldehyde and permeabilized by 0.25%
Triton X-100 were stained as described (Matei et al., 2019).
Primary antibodies used were against EN1 (1:50, #83693; Ab-
cam), P4Hβ (1:50, #MA3-019; Thermo Fisher Scientific), vi-
mentin (1:200, #20346; Abcam), CD45 (1:100, #sc-59070; Santa
Cruz Biotechnology), CD31 (1:100, #AF3628; R&D Systems),
αSMA (1:1,000, #A5228; Sigma-Aldrich), and α-Tubulin (1:500,
#T9026; Sigma-Aldrich). Alexa Fluor–conjugated secondary an-
tibodies (Thermo Fisher Scientific) were used (1:200). Isotype-
matched antibodies were used as negative controls. Stress fibers
were visualized with rhodamine-conjugated phalloidin (1:40,
#R415; Sigma-Aldrich). Nuclei were counterstained using DAPI
(1:800, #sc-3598; Santa, Cruz Biotechnology). The stains of
human or murine skin tissues were analyzed using an Eclipse
80i microscope (Nikon), and quantification of percentages of
EN1-positive fibroblasts was performed using a custom Cell-
Profiler 3.0 pipeline (McQuin et al., 2018). Voronoi tessellation
of immunofluorescence stainings was performed using Fiji
software as described (Matei et al., 2018; Schindelin et al.,
2012). The stains of cultured cells were analyzed using the
CellInsight CX5 High Content Screening Platform (Thermo
Fisher Scientific), and average or total intensity per cell was
automatically quantified using a custom pipeline in HCS
Studio Cell Analysis software and represented as a violin plot
for each condition using ggplot2.
IMC: Staining and data analysis
IMC was performed as described (Giesen et al., 2014). The an-
tibodies were acquired preconjugated (Fluidigm) or in purified
Quantification of dermal thickness (J), myofibroblast counts (K), and hydroxyproline content (L), with figure legend under the plots (scale bars = 500 µm). All
data for A–L are represented as median ± interquartile range of n ≥ 5 independent biological samples per group from at least two independent experiments. P
values are expressed as follows: *, 0.05 > P > 0.01; ***, P < 0.001 (ANOVA with Tukey’s post hoc test).
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preparations. All the purified antibodies were first validated
by standard immunofluorescence staining. Purified antibodies
were consequently conjugated to lanthanide metals using the
Maxpar X8 antibody labeling kit (Fluidigm) following the
manufacturer’s instructions. The complete panel was once more
validated in IMC, and all the antibodies were titrated in IMC.
Paraffin-embedded skin sections (5 µm) were deparaffinized
with xylene for 30 min and rehydrated in a graded series of
alcohol (ethanol:deionized water 100:0, 100:0, 90:10, and 80:20
for 5 min each). For epitope retrieval, the slides were incubated
for 30 min in preheated Tris-EDTA buffer (10 mM Tris base,
1 mM EDTA, and 0.05% Tween 20, pH 9). After slides were
cooled, they were blocked with 2% BSA in PBS for 1 h at room
temperature. Samples were incubated overnight at 4°C with the
metal-labeled antibody mix (in 0.5% BSA). The antibodies are
listed in Table S3. Tissue samples were washed once in PBS-T
(PBS and 0.2% Tween 20) and twice in PBS for 5 min each.
DNA staining was performed with Iridium-Intercalator (125 µM)
1/400 for 5 min at room temperature. Afterward, the samples
were washed three times in PBS and once in deionized water for
5 min each. Finally, the tissue sections were dried, stored, and
shipped at room temperature.
Imaging was performed using a Hyperion Imaging System
(Fluidigm) by the group of Prof. Dr. Bertram Bengsch (Depart-
ment of Medicine II: Gastroenterology, Hepatology, Endocrinol-
ogy, and Infectious Disease, UniversityMedical Center Freiburg).
The MCD files were converted to TIFF format, segmented into
single cells using a publicly available analysis pipeline (https://
zenodo.org/record/3841961), and analyzed with histoCAT with
logarithmic data normalization (Schapiro et al., 2017) and FlowJo
software (BD Life Sciences). Before applying the Phenograph
clustering (Levine et al., 2015), all epithelial cells (E-cadherin+)
and immune cells (CD45+) were excluded. Finally, t-distributed
stochastic neighbor embedding (tSNE) plots were generated
using a custom Python script.
ROCK activity assay
The activity of ROCK in lysates of human fibroblasts was mea-
sured by ROCK activity assay according to the manufacturer’s
instructions (#CSA001; Millipore).
Statistics
All data are presented as median ± interquartile range. For a
two-group comparison, Mann–Whitney U test for nonparamet-
ric data was used. When more than two groups of samples were
compared, one-way ANOVA with Tukey’s range test as post hoc
analysis was used. P values <0.05 were considered statistically
significant. P values are expressed as follows: *, 0.05 > P > 0.01;
**, 0.01 > P > 0.001; and ***, P < 0.001. GraphPad Prism software
v8.0 was used for statistical analysis. The sample size was es-
timated based on previous experiments. No statistical method
was used to predetermine sample size.
Online supplemental material
Fig. S1 shows EN1 expression in healthy and SSc skin in endo-
thelial cells, leukocytes and keratinocytes, as well as composi-
tions of IMC clusters and EN1 expression across clusters in
dorsal and ventral skin. Fig. S2 shows that knockout of En1 in
murine fibroblasts prevents TGFβ-induced fibroblast activation.
Fig. S3 represents the effects of EN1 overexpression on IL-11–,
IL-13–, and CTGF-induced fibroblast activation. Fig. S4 lists the
transcription factors with enriched binding motifs in the pro-
moters of EN1-DEGs and the transcription factors with predicted
cobinding with EN1-SP-DEGs with enriched motifs only in up-
or down-regulated DEGs. Fig. S5 shows that knockdown of EN1
prevents myofibroblast differentiation by inducing microtubule
stabilization. Table S1 lists the primers used for quantitative
real-time PCR. Table S2 lists the clinical data of the SSc patients.
Table S3 lists the antibodies used in the IMC panel. Table S4 and
Table S5 show transcription factor binding site enrichments in
the promoters of EN1-DEGs and EN1-SP-DEGs, respectively.
Table S6 shows functional enrichment analysis of the EN1-SP-
DEGs.
Data availability
All data generated or analyzed during this study are included in
this published article (and supplemental files). Additional sup-
porting information are available from the corresponding au-
thor on reasonable request.
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Figure S1. EN1 expression in healthy and SSc skin. (A–C) Representative immunofluorescence stainings for EN1 (green) and costainings with CD31 (A) and
CD45 (B; both magenta) in the dermis of healthy donors and SSc patients at 1,000-fold magnification (scale bars = 20 µm). Hematoxylin and eosin stainings
(200-fold magnification, scale bars = 100 µm) are included. Data for A–C were obtained from n ≥ 4 biological samples from two independent experiments.
(D) Composition of clusters from the segmented IMC images in ventral and dorsal skin biopsies from SSc patients. (E) tSNE plot showing distribution of cells
from ventral and dorsal SSc skin across clusters. (F) tSNE plot showing expression of EN1 across the ventral and dorsal SSc clusters. Data for D–F were
obtained from n = 8 biological samples from four SSc patients (paired ventral and dorsal biopsies).
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Figure S2. Knockout of En1 ameliorates TGFβ-induced fibroblast activation. (A) Representative immunofluorescence stainings for En1 (green) and
costaining with Vimentin (red) in the dermis of mice with fibroblast-specific knockout of En1 and controls, both groups challenged with bleomycin, at 1,000-fold
magnification (scale bars = 20 µm). Data were obtained from one experiment (n = 4). (B) En1 protein levels (representative Western blot images). Data were
obtained from one experiment (n = 3). (C) Relative mRNA levels of Col1a1 and Col1a2. (D) Secreted collagen 1 protein levels. (E) Relative mRNA levels of Acta2.
Data for C–E were compiled from two independent experiments (n ≥ 4). (F) Representative immunofluorescence stainings for αSMA (green) and stress fibers
(red) at 400-fold magnification (scale bars = 50 µm). Quantification of signal intensity relative to control is included. Data for F were obtained from two
independent experiments (n ≥ 4). All data are represented as median ± interquartile range. P values are expressed as follows: **, 0.01 > P > 0.001; ***, P <
0.001 (ANOVA with Tukey’s post hoc test).
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Figure S3. EN1 overexpression promotes IL-11–, IL-13–, and CTGF-induced fibroblast activation and ECMdeposition to a lesser extent than TGFβ-induced
fibroblast activation and ECM deposition. (A and B) Representative immunofluorescence stainings for fibronectin (A) and collagen type I (B) at 100-fold
magnification (scale bars = 200 µm). Quantification of average signal intensity (relative to control) is included. (C and D) Representative immunofluorescence
stainings for αSMA (C) and stress fibers (D) at 200-fold magnification (scale bars = 100 µm). Quantification of average signal intensity for each cell line (relative
to control) is included. All data are represented as median ± interquartile range of n ≥ 3 independent biological samples per group from at least two inde-
pendent experiments. P values are expressed as follows: *, 0.05 > P > 0.01; **, 0.01 > P > 0.001; ***, P < 0.001 (ANOVA with Tukey’s post hoc test). Data for
A–D were obtained from two independent experiments (n = 4).
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Figure S4. EN1 promotes formation of SP1/2/3/8-containing regulatory modules with specialized profibrotic function. (A) Transcription factors with
enriched binding motifs in the promoters of up- and down-regulated EN1-DEGs, with gene ratio in EN1-DEGs (ratio of genes that contain motifs for the
respective transcription factor) more than twofold higher than the gene ratio in negative controls, colored by families. (B) Circular packing plots illustrating
predicted SP1/2/3/8 (SP) binding in the promoters of up- and down-regulated EN1-DEGs and cobinding with other members of the C2H2 or E2F families and
with NFYB or TFDP1, expressed as percentages.
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Figure S5. Knockdown of EN1 stabilizes the microtubular network to inhibit stress fiber formation and myofibroblast differentiation. (A and B)
Knockdown of EN1 stabilizes microtubules. Representative immunofluorescence stainings for α-Tubulin at 400-fold magnification (scale bars = 50 µm).
Quantification of total signal intensity for each cell (relative to control) is included (A). Protein levels of soluble and insoluble α-Tubulin. RepresentativeWestern
blot images and quantification of insoluble/soluble α-Tubulin ratio are included (B). Data for A and B were obtained from two independent experiments (n ≥ 4).
(C–G) Pharmacological depolymerization of microtubules abrogates the inhibitory effects of EN1 knockdown on TGFβ-induced myofibroblast differentiation.
Relative mRNA levels of COL1A1 (C). Relative protein levels of secreted collagen type I (D). Relative mRNA levels of ACTA2 (E). Representative immunofluo-
rescence stainings for αSMA (F) and stress fibers (G) at 400-fold magnification (scale bars = 50 µm). Data for C–G were obtained from two independent
experiments (n ≥ 4). Quantification of average signal intensity for each cell (relative to control) is included. All data are represented as median ± interquartile
range. P values are expressed as follows: *, 0.05 > P > 0.01; **, 0.01 > P > 0.001; ***, P < 0.001 (ANOVA with Tukey’s post hoc test).
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Provided online are six tables. Table S1 lists primers used for quantitative real-time PCR. Table S2 shows the clinical data of SSc
patients. Table S3 lists the antibodies used in the imaging CyToF panel. Table S4 shows transcription factor binding site
enrichments in the promoters of EN1-DEGs. Table S5 shows transcription factor binding site enrichments in the promoters of
EN1-SP-DEGs. Table S6 shows functional enrichment analysis of EN1-SP-DEGs.
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